DXCMDexcom

$84.10+11% 1Y

$84.10

$54.8452 weeks$92.35

DXCM in its own filings

Nothing in DXCM's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.

407

Events found in the filings · across 2,644 filings · the record starts in 2005

Hard flags: none
Hard flags
Most recent filing: Sep 14, 2026
Most recent filing · Form 8-K
Record starts: Feb 25, 2005
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Oct 29, 2026
Change in certifying accountantpast_3y: 2025-03-25
SEC comment-letter activity18 occurrences: 2022-05-05

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Sep 14, 2026On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jereme Sylvain, the Company’s EVP, Chief Financial Officer, to the role of EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026.Director or officer change · Form 8-K
Sep 10, 2026On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to thirteen directors and appointed Glenn S. Boehnlein as a director, effective immediately.Director or officer change · Form 8-K
Jul 30, 2026Dexcom Reports Second Quarter 2026 Financial Results.Earnings release · press release
May 15, 2026On May 14, 2026, Dexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of Dexcom’s outstanding common stock, par value $0.001 per share (“Common Stock”), with a repurchase period ending no later than June 30, 2027 (the “Share Repurchase Program”)Regulation FD disclosure · Form 8-K
Apr 30, 2026Dexcom Reports First Quarter 2026 Financial Results.Earnings release · press release
Mar 2, 2026As previously reported on the Current Report on Form 8-K filed on July 30, 2025, Kevin R. Sayer notified the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) of his intent to retire from his role as Chief Executive Officer effective January 1, 2026.Director or officer change · Form 8-K
Feb 26, 2026On February 26, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to twelve directors and appointed Albert F. (“Rick”) Osterloh, IV as a director effective immediately.Director or officer change · Form 8-K
Feb 12, 2026Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results.Earnings release · press release
Jan 12, 2026Dexcom Enters Next Era of Continued Innovation with Jake Leach as President and Chief Executive Officer.Earnings release · press release
Dec 22, 2025As previously reported on the Current Report on Form 8-K filed on July 30, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jacob S. Leach, President and Chief Operating Officer, as the President and Chief Executive Officer and as a director of the Company, effective …Director or officer change · Form 8-K
Oct 30, 2025Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance.Earnings release · press release